Biotech Values

[DewDiligence]

(MNTA)—NVS’ 3Q12 sales of generic Lovenox shrank drastically to $34M (from $156M in 2Q12) due to increased competition and consequent pricing erosion. In 2Q12, WPI/Amphastar had their generic product on the market for only part of the quarter (after the preliminary injunction was stayed by the Appellate Court in late January).

In today’s press release re 3Q12, NVS cited “aggressive competitor pricing on enoxaparin” (http://www.sec.gov/Archives/edgar/data/1114448/000137036812000077/a121025-99_2.htm page 14).

MNTA reports 3Q12 financial results on 11/7/12.